Bruker Corporation
HealthcareNASDAQ:BRKR · NASDAQ Global Select
-$0.95 today
Vol 2.19M · Avg 2.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.4%
avg 17.7%
ROIC
-1.9%
avg 8.4%
ROA
-0.1%
avg 6.1%
Analysis
ROA is currently the strongest return metric at -0.1% versus its period average of 6.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Frank H. Laukien | Chairman, Chief Executive Officer & President | $1.59M | — | 66 | $38.49M | 25.29% |
Mark R. Munch | Corporate Executive Vice President and President of Bruker Nano Group & Corporate | $1.12M | — | 64 | $130,443.00 | 0.09% |
Gerald N. Herman | Executive Vice President & Chief Financial Officer | $879,311.00 | — | 67 | $102,583.00 | 0.07% |
Falko Busse | President of Bruker BioSpin Group | $822,109.00 | — | 59 | $48,171.00 | 0.03% |
Juergen Srega | President of Bruker CALID Group & Bruker Daltonics Division | $772,590.00 | — | 71 | $157,727.00 | 0.10% |
Burkhard Prause | President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc. | $595,963.00 | — | 59 | $25,158.00 | 0.02% |
Thomas Bures | Chief Accounting Officer | — | — | 51 | $3,198.00 | <0.01% |
J. Brent Alldredge | Senior Vice President, General Counsel, Secretary & Global Head of Compliance | — | — | 51 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$3.08M
Net Sentiment
$3.08M
Net selling
Most Active
Munch Mark
9 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $3.08M over the last 12 months. That adds up to net selling of $3.08M. Munch Mark was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +9.3% | +12.3% (15yr)1 analysts |
| Revenue | N/A | N/A | -3.2% | +6.7% (15yr)6 analysts |
| Net Income | N/A | N/A | +9.4% | +11.5% (15yr)6 analysts |
| EBIT | N/A | N/A | -2.3% | +9.1% (15yr)6 analysts |
Analysis
Recent growth has been strongest in Net Income at +9.4% over three years. Forward estimates point to EPS at +12.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.26B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.37B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Glaukos Corporation
NYSE:GKOS
$7.45B
Teleflex Incorporated
NYSE:TFX
$5.78B
Chemed Corporation
NYSE:CHE
$5.57B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.97B
iRhythm Technologies, Inc.
NASDAQ:IRTC
$3.73B
TransMedics Group, Inc.
NASDAQ:TMDX
$2.52B
Who manages BRKR?
Bruker Corporation (BRKR) lists 8 active executives. The top listed executive is Juergen Srega, President of Bruker CALID Group & Bruker Daltonics Division.
Are BRKR insiders buying or selling?
Recent insider activity shows net buying of $15.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.